Influence of diabetes mellitus on heart failure risk and outcome - sprookjes - yvandenbroek - TriplyDB

Influence of diabetes mellitus on heart failure risk and outcome

Influence of diabetes mellitus on heart failure risk and outcome

http://www.wikidata.org/entity/Q24800363

about

Screening for asymptomatic coronary artery disease in patients with diabetes mellitus: A systematic review and meta-analysis of randomized trials Cardiac Imaging in Heart Failure with Comorbidities.The current role of thiazolidinediones in diabetes management.Therapy insight: heart disease and the insulin-resistant patient.Diabetes is associated with impaired myocardial performance in patients without significant coronary artery disease.Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.Prevalence and comorbidities of known diabetes in northeastern Italy.Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation Prevalence of QT prolongation and associated LVEF changes in diabetic patients over a four-year retrospective time period Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway Structural arrangement of the cardiac collagen fibers of healthy and diabetic dogs.Stem cells as a therapeutic target for diabetes.Small engine, big power: microRNAs as regulators of cardiac diseases and regeneration.Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study Imaging the effect of receptor for advanced glycation endproducts on angiogenic response to hindlimb ischemia in diabetes.MuRF2 regulates PPARγ1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet.Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes.Heart failure in sub-Saharan Africa: a literature review with emphasis on individuals with diabetes.Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome.Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study.Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats.Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?Diabetic neuropathy and heart failure: role of neuropeptides.Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy.Incretins as a novel therapeutic strategy in patients with diabetes and heart failure.Endothelial dysfunction and hypertension in aging.Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage.Long-term survival following the development of heart failure in an elderly hypertensive population.What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?Effect of Nigella sativa supplementation over a one-year period on lipid levels, blood pressure and heart rate in type-2 diabetic patients receiving oral hypoglycemic agents: nonrandomized clinical trial.Toward a continuous intravascular glucose monitoring system.Ginsenoside Rh2 Improves Cardiac Fibrosis via PPARδ-STAT3 Signaling in Type 1-Like Diabetic Rats.Natriuretic Peptide System Activation in Acute Heart Failure Patients with Diabetes Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway.Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E.Nephropathy, but not retinopathy, is associated with the development of heart disease in Type 1 diabetes: a 12-year observation study of 462 patients.Heart failure in diabetes mellitus: clinical features and prognostic implications.Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus.Cardiac Insulin Signaling Regulates Glycolysis Through Phosphofructokinase 2 Content and Activity.

P2860

Q28067628-F0943E03-68CA-407B-86C6-25200E826C42 Q30248624-A73C961A-6433-4AC5-A1D3-FC79610E578A Q30250347-93A4B938-1A5E-46EA-A18D-1DB500EE6B9C Q30351748-286B5A0E-53D7-4140-BDD6-FEE8F75183EA Q30483398-C686E05B-1340-4F59-937E-2A7FE3081759 Q33354126-51B36F8C-91A4-492F-B257-931B21101D37 Q33607611-EDEDCA19-01DA-4F3D-92AE-C49112017357 Q33804265-4E8EB681-4221-4939-8C99-C847A4AE3FD1 Q33806055-7FE68168-8360-42A8-BB4B-747AE2C1AA12 Q33835169-AA4C38C2-4F0C-440C-B648-6719C8E5B24B Q33870108-F1247EA5-B421-4AE2-9F5C-B30D87B80E71 Q33982394-5EED4CDB-C6FE-4F5A-946E-43E3ECF03DC7 Q34358827-1A201257-AA64-4F66-9EB4-68782D82893B Q35073928-300C07AB-1F57-472C-AC36-A32FCC52D46F Q35335414-82CB0E0F-BBD5-49D5-952E-5A49FB7C4969 Q35920226-45876672-FD58-4373-9288-3B819BC9F94C Q36547048-FD16BEB3-E791-4C35-8A93-5E1C769504BA Q36766997-36A06717-27E8-45FA-ABF7-D1986A27583C Q36902706-2826A51D-2B2C-40FE-A39A-CF2E1EC59919 Q37066737-84AC9CDF-8C26-4139-8755-049B4ABCCAA3 Q37187342-33DB684A-998A-4F92-ACC4-40D91B77E94C Q37360093-63CA11AC-6506-424A-9C81-12077804A873 Q37737932-9675CE14-350C-4F7D-89E9-9170D1AC68EE Q37914972-28A9EBD5-121F-4611-91F5-B0AFA790B2B1 Q37951439-347A8E2B-177F-4DA7-AFF4-0D451B857D72 Q38008596-2749F7B0-D548-4244-BCDB-F5D5C7CE645D Q38042870-50114C1C-7BD1-4435-B988-7A904B6B0CFA Q38271210-A0245474-C506-4160-8775-5A86143A5B4E Q38599662-7344F5AE-049C-48E9-A039-C12DE3D236CE Q38931845-E7F88808-C7C7-40F2-AF23-EFE2EC3520C9 Q38984580-CAFD4B82-096C-4E2B-A2BD-4317616A1370 Q40907773-7036090C-DA18-4D63-91EA-5C3FD85C3498 Q41181423-E5D13A96-B3FA-4698-A357-4FCDA377A889 Q41448269-9326A02D-B5D9-4069-825E-E25CC1085796 Q43174462-01D5D84D-D3DC-4499-BDFB-F2BE1C241485 Q45042361-666871CE-23D1-442C-8A03-3824A9C9C245 Q45232377-54DD0FB8-FD0A-416B-B538-3CB0E9CA86FC Q46398793-74AA5698-49A7-4F72-B056-0FD588B7C97C Q47214520-BACC459D-5BF2-4F76-B539-6AA4373BEDC6 Q47332502-113A4FB0-3BBC-4897-80C7-E03545840183

P2860

Influence of diabetes mellitus on heart failure risk and outcome

http://www.wikidata.org/entity/Q24800363

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Influence of diabetes mellitus on heart failure risk and outcome

@ast

Influence of diabetes mellitus on heart failure risk and outcome

@en

Influence of diabetes mellitus on heart failure risk and outcome

@nl

type

label

Influence of diabetes mellitus on heart failure risk and outcome

@ast

Influence of diabetes mellitus on heart failure risk and outcome

@en

Influence of diabetes mellitus on heart failure risk and outcome

@nl

prefLabel

Influence of diabetes mellitus on heart failure risk and outcome

@ast

Influence of diabetes mellitus on heart failure risk and outcome

@en

Influence of diabetes mellitus on heart failure risk and outcome

@nl

P1433

Q24800363-AF630D8D-D923-41AE-A3E2-37DE8B69CC8D

P1476

Q24800363-5897507F-A6D4-40C9-8CBD-1384DCCFF255

P2093

Q24800363-268B7EB7-6257-4F3C-B310-1D070471E13E

Q24800363-EC9ECDB2-72A0-4462-9206-188791AE9207

P2860

Q24800363-006066DD-8FE9-45B7-A56E-C0302983ADAB

Q24800363-018CDCA8-1A47-4503-AC0A-CC9FEA6BB101

Q24800363-01EA9D39-A0FF-4037-9207-7241E36FE26A

Q24800363-040A701D-B62A-4DB3-B314-B4F9F802391C

Q24800363-052DB454-86C1-45C9-8F54-937AECB888D2

Q24800363-0D34189F-9222-4B2F-8182-539C5C3E52D7

Q24800363-10344C97-785C-4D40-BBA6-00F6731B9122

Q24800363-128A9BE1-9B1C-49E8-B4F5-C3FEF894D0E0

Q24800363-16824BB6-7814-41FA-B32B-172A459A5CE7

Q24800363-1BE6F2EB-7B5C-465F-8522-B60AC53E0C56

P2888

Q24800363-1BB3B2D8-F596-4996-9DF7-DB536FB06CD5

P304

Q24800363-4F57D0A7-C4AD-4645-878F-B83BA1E82BE9

P31

Q24800363-30B203FA-51D0-411E-A10C-D84EEC2BF64F

P3181

Q24800363-C8B97E31-517F-4EF6-956D-AE24E472B914

P356

Q24800363-38AB6568-9B72-41A0-8B8E-95BB18ECF58C

P407

Q24800363-F1FF43BC-C3A7-4116-8649-32B92ADA04C2

P433

Q24800363-7A66C2F1-21D7-4C98-A3B1-64E7162146DA

P478

Q24800363-0938A3A0-54E0-46CF-9990-8A7D72DE17AD

P50

Q24800363-61B08150-4434-4CA4-862F-28996A49D59D

Q24800363-6EC845C3-1B97-43EE-9570-EAAD69CBA11D

Q24800363-8527851D-F2A1-4582-B920-AB0B45AF65D7

Q24800363-A92D8118-9B6A-41E7-B510-5571CE47499C

P577

Q24800363-19877625-079B-40C8-9F76-F28B275FDC49

P5875

Q24800363-249C3867-E974-459A-930E-E28418E3FC97

P6179

Q24800363-4902AB11-4332-424B-975A-55283A5CF122

P698

Q24800363-D1A2CD1E-3088-4EAE-8215-5ED1AFAEE193

P921

Q24800363-C97321AE-A1BC-4BC3-A087-863697039222

P932

Q24800363-21203D36-50D4-4E8F-9ADF-4D2F2EED72CA

P3181

P356

P1433

Cardiovascular Diabetology

P1476

Influence of diabetes mellitus on heart failure risk and outcome

@en

P2093

Alain Millaire

http://www.w3.org/2001/XMLSchema#string

Eugène P Mc Fadden

http://www.w3.org/2001/XMLSchema#string

P2860

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

How hyperglycemia promotes atherosclerosis: molecular mechanisms.

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

P2888

P304

1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

451617

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1475-2840-2-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Lamblin

Pascal de Groote

Christophe Bauters

P577

2003-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10927681

http://www.w3.org/2001/XMLSchema#string

P6179

1002234103

http://www.w3.org/2001/XMLSchema#string

P698

12556246

http://www.w3.org/2001/XMLSchema#string

P921

P932

149427

http://www.w3.org/2001/XMLSchema#string